The Authority on
Low-Dose Ketamine
Low-Dose Ketamine: Troches, Tablets & Oral Formulations
Comprehensive Guides
Deep-dive clinical and patient-focused guides.
The Complete Guide to Low-Dose Ketamine Therapy
A comprehensive, evidence-based guide covering what low-dose ketamine is, how it works, all routes of administration, what patients can expect during treatment, efficacy data across conditions, safety considerations, and how to find qualified providers.
Ketamine Dosing and Administration: A Complete Clinical Guide
A comprehensive clinical reference for ketamine dosing across all routes of administration. Covers pharmacokinetics, weight-based dosing, dose-response relationships, titration strategies, route-specific protocols, special population considerations, and monitoring requirements.
Ketamine for Depression: A Comprehensive Evidence-Based Guide
An in-depth clinical guide examining the evidence for low-dose ketamine in the treatment of major depressive disorder and treatment-resistant depression. Covers mechanisms of action, clinical trial data, response predictors, duration of effect, maintenance strategies, and cost-benefit analysis.
Interactive Tools
IV Racemic Ketamine vs Esketamine (Spravato): A Clinical Comparison
ComparisonKetamine vs TMS (Transcranial Magnetic Stimulation): Two Approaches to Treatment-Resistant Depression
ComparisonSublingual vs Oral (Swallowed) Ketamine: Absorption and Efficacy Differences
Esketamine's Role in Treatment-Resistant Depression
A new clinical overview examines esketamine's place in TRD care, including patient selection, access barriers, and rapid-acting benefits for suicidal ideation.
Glutamate Pathway Treatments Reshape TRD Care in 2026
A 2026 review in Psychiatric Times highlights how esketamine and glutamate-targeting drugs are changing treatment-resistant depression care.
TRD Management: Why Remission Should Be the Goal
New clinical guidance on treatment-resistant depression urges full remission over symptom reduction — here's what it means for low-dose ketamine patients.
TRD Experts Push for Remission, Not Just Response
Psychiatrists are shifting TRD goals from symptom reduction to full remission. Here's what that means for ketamine patients and their treatment plans.
Beyond 'Less Bad': Rethinking Treatment-Resistant Depression
Clinicians are pushing beyond symptom reduction in treatment-resistant depression, aiming for full remission. Here's what that means for ketamine patients.
Why Clinicians Are Pushing Harder on TRD Goals
New clinical thinking on treatment-resistant depression pushes toward true remission, not just symptom reduction. Here's what it means for ketamine patients.